Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma.
Ailawadhi S, Miecznikowski J, Gaile DP, Wang D, Sher T, Mulligan G, Bryant B, Wilding GE, Mashtare T, Stein L, Masood A, Neuwirth R, Lee KP, Chanan-Khan A.
Ailawadhi S, et al. Among authors: mashtare t.
Leuk Lymphoma. 2012 Jun;53(6):1174-82. doi: 10.3109/10428194.2011.637212. Epub 2011 Dec 6.
Leuk Lymphoma. 2012.
PMID: 22054286